SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-046847
Filing Date
2022-04-18
Accepted
2022-04-18 16:01:38
Documents
6
Period of Report
2022-06-01

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm223661-1_def14a.htm DEF 14A 660939
2 GRAPHIC lg_kerostherapeutics-4clr.jpg GRAPHIC 19480
3 GRAPHIC sg_jasbirseehra-4c.jpg GRAPHIC 14456
4 GRAPHIC sg_esthercho-bw.jpg GRAPHIC 7166
5 GRAPHIC tm223661d1-pxy_proxy1bw.jpg GRAPHIC 1052074
6 GRAPHIC tm223661d1-pxy_proxy2bw.jpg GRAPHIC 1305472
  Complete submission text file 0001104659-22-046847.txt   3962471
Mailing Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421 617-513-8774
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39264 | Film No.: 22832148
SIC: 2834 Pharmaceutical Preparations